Nuvo Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development, commercialization and licensing of prescription and consumer healthcare products. Trading on the OTC Markets under the ticker NRIFF, Nuvo leverages its expertise in formulation and regulatory affairs to bring innovative therapies to market. The company’s core activities encompass the identification of niche therapeutic opportunities, the in-house development of novel drug delivery systems and the strategic out-licensing of intellectual property to global partners.
The company’s product portfolio includes prescription drugs such as Pennsaid, a topical diclofenac solution indicated for osteoarthritis pain of the knee, and Sialor gel, a pilocarpine-based treatment for oral mucositis in cancer patients. In addition, Nuvo has introduced Maxigesic, an oral combination of acetaminophen and ibuprofen marketed in select territories for acute pain management, and Relizon, a homeopathic sleep-aid available over the counter. Through ongoing clinical programs, the company seeks to expand indications and dosage forms for its lead assets.
Nuvo Pharmaceuticals operates primarily in North America and Europe, with its headquarters in Mississauga, Ontario, Canada. The company’s manufacturing and distribution network spans multiple contract facilities in Canada, the United States and the United Kingdom, enabling efficient supply chain management and market access. Nuvo regularly engages with regulatory agencies such as Health Canada, the U.S. Food and Drug Administration and the European Medicines Agency to support product registrations and post-market surveillance activities.
Founded in the late 1980s, Nuvo has grown from a research-focused start-up into a diversified specialty pharma organization. Its leadership team, headed by President and CEO John Rapalje, brings decades of combined experience in drug development, commercialization and corporate strategy. Supported by a board of directors with deep industry knowledge, Nuvo continues to pursue partnerships and in-licensing opportunities that complement its existing product lines while advancing its goal of improving patient care through targeted pharmaceutical innovations.
AI Generated. May Contain Errors.
Free NRIFF Stock Alerts